

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6749395

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	BIOLUX RESEARCH INC.	03/15/2021
RECEIVING PARTY DATA		
Name:	LLLT TECHNOLOGIES SA	
Street Address:	CHEMIN DU COURSON 11	
City:	ANIERES	
State/Country:	SWITZERLAND	
Postal Code:	1247	
PROPERTY NUMBERS Total: 3		
Property Type	Number	
Patent Number:	10729524	
Patent Number:	9242118	
Patent Number:	9730780	
CORRESPONDENCE DATA		
Fax Number:	(860)286-0115	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	8602862929	
Email:	usptopatentmail@cantorcolburn.com	
Correspondent Name:	CANTOR COLBURN LLP	
Address Line 1:	20 CHURCH STREET, 22ND FLOOR	
Address Line 4:	HARTFORD, CONNECTICUT 06103	
ATTORNEY DOCKET NUMBER:	NO70125US	
NAME OF SUBMITTER:	DANIEL F. DREXLER	
SIGNATURE:	/Daniel F. Drexler/	
DATE SIGNED:	06/08/2021	
Total Attachments: 7		
source=8RK9755#page1.tif		
source=8RK9755#page2.tif		
source=8RK9755#page3.tif		
source=8RK9755#page4.tif		

source=8RK9755#page5.tif

source=8RK9755#page6.tif

source=8RK9755#page7.tif

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT is made as of March 15, 2021, by and between Biolux (ABC), LLC, a Delaware limited liability company ("Seller"), as Assignee for the Benefit of Creditors of Biolux Research Holdings, Inc., a Delaware corporation, and LILT Technologies SA, a Swiss Corporation ("Buyer"), as successor in interest to Biolux Technology GmbH, an Austrian limited liability company. Seller and Buyer are parties to a certain Asset Purchase Agreement dated as of March 15, 2021, (the "Asset Purchase Agreement"). Capitalized terms used without definitions herein shall have the meanings ascribed to such terms in the Asset Purchase Agreement.

WHEREAS, Seller has agreed to sell to Buyer, and Buyer has agreed to acquire from Seller, all of Seller's rights, title and interest in all patents and patent applications owned by Seller, including those patents and patent applications identified in Schedule A attached herein ("Assigned Patents"); and

WHEREAS, the parties accordingly wish to execute this recordable instrument, assigning all of Seller's right, title and interest in and to the Assigned Patents to Buyer;

NOW, THEREFORE, for valuable consideration set forth in the Asset Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, Seller and Buyer agree as follows:

1. Seller hereby sells, assigns, transfers, and sets over to Buyer, and its lawful successors and assigns, the Seller's entire right, title, and interest throughout the world in and to the Assigned Patents, together with all rights to the inventions described or claimed therein, and all divisions, continuations and continuations-in-part thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority therefrom, and all applications for Letters Patent which may hereafter be filed for this invention in any foreign country and all Letters Patent which may be granted on this invention in any foreign country, and all extensions, renewals, and reissues, thereof and Seller hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for any invention disclosed and claimed in any Assigned Patent to Buyer, its successors and assigns, in accordance with the terms of this Patent Assignment Agreement.


2. Seller further assign to Buyer all rights to sue and recover for any past, present or future actions, causes of action and rights to recover damages or payments (including lost profits), for infringement or misappropriations of any Assigned Patent, as well as the right to take over and continue any and all existing suits related to any Assigned Patent.

3. This Patent Assignment Agreement is subject to the terms and conditions of the Asset Purchase Agreement and this Patent Assignment Agreement shall not be deemed to limit, enlarge or extinguish any obligation of Seller or Buyer under the Asset Purchase Agreement, all of which obligations shall survive the delivery of this Patent Assignment Agreement in accordance with the terms of the Asset Purchase Agreement, and that to the extent there is any conflict between this Patent Assignment Agreement and the terms and conditions of the Asset Purchase Agreement, the Asset Purchase Agreement shall control.

4. This Patent Assignment Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

SELLER:

Biolux (ABC), LLC, a Delaware limited liability company, as Assignee for the Benefit of Creditors of Biolux Research Holdings, Inc.


By: 

Name: David Miller

Title: Manager

BUYER:

LLLT Technologies SA, a Swiss Corporation

By: 

Name: Marcel C. Pordes

Title: Managing Director

PATENT ASSIGNMENT AGREEMENT Final.docx

Schedule A
To Patent Assignment Agreement

Patents & Patent Applications

Application No.	Application Date	Patent No.	Patent Date	Country
06710427.3	2/17/2006	1853347	4/11/2012	European Patent Office
201080032056.5	6/8/2009	ZL201080032056.5	3/22/2017	China
2012-513427	6/8/2009	5705838	3/6/2015	Japan
10-2012-7000429	6/7/2010	10-1670537	10/24/2016	Republic of Korea
13/314,006	12/7/2011	9,242,118	1/26/2016	United States of America
PCT/US2019/063197	11/26/2019			Patent Cooperation Treaty
06710427.3	2/17/2006	602006028746.1	4/11/2012	Germany
06710427.3	2/17/2006	1853347	4/11/2012	United Kingdom
06710427.3	2/17/2006	1853347	4/11/2012	France
6/575,119	9/18/2019			United States of America
11831892.2	10/12/2011	2627283	9/23/2015	European Patent Office
13/895,330	5/15/2013	8,900,282	12/2/2014	United States of America
11846346.2	12/7/2011	2648651	11/23/2016	European Patent Office
14/521,121	10/22/2014	9,730,780	6/6/2017	United States of America
14/521,121	10/22/2014	9,730,780	8/15/2017	United States of America
201380032437.7	4/19/2013	ZL201380032437.7	10/26/2016	China
13779083.8	4/19/2013	2838468	5/17/2017	European Patent Office
2015-506056	4/19/2013	6007313	9/16/2016	Japan
14/554,404	5/15/2013	9,308,389	4/12/2016	United States of America
16/584,386	9/26/2019			United States of America
62/970,129	2/4/2020			United States of America
11831892.2	10/12/2011	2627283	9/23/2015	United Kingdom
11831892.2	10/12/2011	2627283	9/23/2015	Germany
201480057810.9	10/22/2014			China
14855209.4	10/22/2014	3060159	4/1/2020	European Patent Office
2016-525585	10/22/2014	6484235	2/22/2019	Japan

PATENT ASSIGNMENT AGREEMENT Final.docx

Schedule A (Continued)
To Patent Assignment Agreement

Patents & Patent Applications

Application No.	Application Date	Patent No.	Patent Date	Country
17171423.1	4/19/2013	3263066	7/10/2019	Germany
17171423.1	4/19/2013	3263066	7/10/2019	France
17171423.1	4/19/2013	3263066	7/10/2019	United Kingdom
201610842415.2	4/19/2013	ZL201601842415.2	5/7/2019	China
11846346.2	12/7/2011	2648651	11/23/2016	Germany
11846346.2	12/7/2011	2648651	11/23/2016	France
11846346.2	12/7/2011	2648651	11/23/2016	United Kingdom
17171423.1	4/19/2013	3263066	7/10/2019	European Patent Office
13779083.8	4/19/2013	2838468	5/17/2017	France
13779083.8	4/19/2013	2838468	5/17/2017	Germany
13779083.8	4/19/2013	2838468	5/17/2017	United Kingdom
15/858,533	12/29/2017	10,729,524	8/4/2020	United States of America
16/135,842	9/19/2018			United States of America
16/272,670	2/11/2019			United States of America
16/292,224	3/4/2019			United States of America
2019-025547	10/22/2014			Japan
16/428,773	5/31/2019			United States of America
202010068497.6	10/22/2014			China
14855209.4	10/22/2014	3060159	4/1/2020	Germany
14855209.4	10/22/2014	3060159	4/1/2020	France
14855209.4	10/22/2014	3060159	4/1/2020	United Kingdom
16/935,847	7/22/2020			United States of America

[REMAINDER OF PAGE LEFT BLANK]

PATENT ASSIGNMENT AGREEMENT Final.docx

Exhibit 6.2(iii)
TO ASSET PURCHASE AGREEMENT

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT is made as of April 28, 2021, by and between Biolux (ABC), LLC, a Delaware limited liability company ("Seller"), as Assignee for the Benefit of Creditors of Biolux Research Holdings, Inc., a Delaware corporation, and LLLT Technologies SA, a Swiss Corporation ("Buyer"), as successor in interest to Biolux Technology GmbH, an Austrian limited liability company. Seller and Buyer are parties to a certain Asset Purchase Agreement dated as of March 15, 2021, (the "Asset Purchase Agreement"). Capitalized terms used without definitions herein shall have the meanings ascribed to such terms in the Asset Purchase Agreement.

WHEREAS, Seller has agreed to sell to Buyer, and Buyer has agreed to acquire from Seller, all of Seller's rights, title and interest in and to the trademarks and/or service marks identified in Schedule A attached hereto (the "Marks"); and

WHEREAS, the parties accordingly wish to execute this recordable instrument, assigning all of Seller's right, title and interest in and to the Marks to Buyer;

NOW, THEREFORE, for valuable consideration set forth in the Asset Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, Seller and Buyer agree as follows:

1. Seller hereby assigns, transfers and conveys to Buyer all of its right, title and interest in and to the Marks, including without limitation any and all registrations, applications, and/or common law rights for the Marks throughout the world, together with all of the goodwill of Seller's business symbolized by or associated with the Marks, and any and all income, royalties, damages and payments now or hereafter due and/or payable with respect thereto including, without limitation, damages and payments for past, present or future infringements.

2. This Trademark Assignment is subject to the terms and conditions of the Asset Purchase Agreement and this Trademark Assignment shall not be deemed to limit, enlarge or extinguish any obligation of Seller or Buyer under the Asset Purchase Agreement, all of which obligations shall survive the delivery of this Trademark Assignment in accordance with the terms of the Asset Purchase Agreement, and that to the extent there is any conflict between this Trademark Assignment and the terms and conditions of the Asset Purchase Agreement, the Asset Purchase Agreement shall control.

3. This Trademark Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

SELLER:

Biolux (ABC), LLC, a Delaware
limited liability company, as Assignee for
the Benefit of Creditors of Biolux Research
Holdings, Inc.

By: 

Name: David Miller

Title: Manager

BUYER:

LLLT Technologies SA, a Swiss Corporation

By: 

Name: Marcel C. Pordes

Title: Managing Director

TRADEMARK ASSIGNMENT Final.docx

Schedule A
To Trademark Assignment

Marks

Mark	Country	Registration No.
337397-20013 BIOLUX	United States	5088423
337397-20009 ORTHOPULSE	United States	5078503
337397-20010 ORTHOPULSE	Australia	1732687
337397-20003 ORTHOPULSE	Canada	TMA928068
337397-20022 BIOLUX	China	323904389
337397-20016 BIOLUX in Chinese	China	26569480
337397-20012 BIOLUX in Chinese (image)	China	40081485
337397-20007 ORTHOPULSE	China	15715336
337397-20017 ORTHOPULSE in Chinese	China	26563321
337397-20018 ORTHOPULSE in Chinese (image)	China	26567923
337397-20002 ORTHOPULSE	EU	012889093
337397-20014 BIOLUX	Japan	5992326
337397-20008 ORTHOPULSE	Japan	5774093
337397-20005 ORTHOPULSE	Switzerland	668855
337397-20006 ORTHOPULSE	Taiwan	2081854
337397-20002/GB ORTHOPULSE	UK	UK00912889093

[REMAINDER OF PAGE LEFT BLANK]